



INTERNATIONAL COVID-19 CLINICAL EVALUATION REGISTRY:

HOPE-2.

(Health Outcome Predictive Evaluation for COVID 19- 2)

PROTOCOL VERSION 2

ENGLISH VERSION.

NCT04778020

INTRODUCTION.

Since December 2019, when a new respiratory virus (coronavirus) designated as SARS-CoV-2 was detected in China, millions of people worldwide have been infected. This condition was named coronavirus 2019 disease (COVID-19) and has produced a pandemic with millions of casualties.

With an increasing number of confirmed cases in most countries worldwide, it is responsible for a relevant morbidity and mortality and has motivated the implementation of measures at national and international levels with a great impact on the way of life of people throughout the whole planet.

One year after the beginning of the outbreak, several reports and trials have been produced reporting important data about the acute phase of the disease. In this field the International registry HOPE COVID-19 (NCT04334291) has provided several publications with collaborative data from more than 45 centers in 9 countries.

The registry, as well, produced an online mortality calculator based in a few clinical variables (<https://hopeprojectmd.com/en/tool>).

However, limited follow-up information is available and the existing evidence point out frequent lasting effects after the acute phase of COVID-19. This persistent condition has been baptized by several authors with different terms such Post-acute COVID-19, Persistent COVID-19, Post COVID- syndrome, Long haulers, Long COVID-19, etc..

Since COVID-19 have involved and unprecedented numbers of people is possible the sequelae would be important form the socioeconomic and scientific point of view.

Thus, we propose here the international Registry HOPE 2, aiming to produce clinically relevant data regarding the longstanding outcomes after discharge after COVID-19.

PURPOSE.

HOPE2_v2_Last review 14.02.2021



The main objective of the present study is to carefully characterize the clinical profile of individuals with lasting sequelae after a COVID-19 admission.

As secondary objectives, the analysis of the risk-adjusted influence of COVID-19 severity, previous comorbidities and management of patients discharged after COVID-19 will be performed.

DESIGN AND STATISTICAL ANALYSIS

Cross-sectional and prospective registry, a real life “all comers” type, with voluntary participation, without specific funding or conflicts of interest.

It is a study initiated by researcher that will have advanced statistical support from the IMAS foundation (Institute for the Improvement of Health Care, Madrid, Spain) and the Fundación para la Investigación Cardiovascular (FIC, Madrid, Spain).

International level.

PARTICIPANTS PROTOCOL.

The study has been approved by Hospital Clínico San Carlos Ethic’s Committee (**21/128-E**) and the institutional board of each participating center.

The present study proposes the continuation in time of the work previously carried out in the HOPE registry.

We propose to select all the patients attended in any health center (with in hospital beds), who have been discharged or have died up to 30th september 2020.

All will be considered eligible with a positive COVID 19 test (any type) or if their attending physicians consider them highly likely to have presented the infection.

Given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.

- **Inclusion criteria**

Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion.

There are no exclusion criteria, except for the patient's explicit refusal to participate.

HOPE2_v2_Last review 14.02.2021



Same inclusion/exclusion as HOPE COVID-19. We propose the long-term follow-up of patients discharged after a COVID-19 admission up to 30th september 2020.

Consecutive inclusion and the completion of patients previously included in HOPE registry is strongly warranted.

DATA BASE.

An anonymized HOPE 2 database is presented, in electronic format, to be filled in at each participating center (www.HopeProjectMD.com).

In theory, most information could be obtained from electronic records (medical history).

Probably, the investigator should call or use in office visits in order to establish the vital the long-term management and follow-up outcomes (warranted).

For variables definition, please see protocol appendix.

SAMPLE SIZE.

We consider it would not be possible to estimate for the sample size based on literature reports. Thus, HOPE2 will aim to get the maximum numbers of patients possible.

Researchers are warranted to recruit their patients in a consecutive manner.

OUTCOMES.

Primary: All-cause mortality. The major contributors of increased mortality will be assessed.

Secondary: Cause of death and Outcomes after discharge.

See protocol appendix for precise definitions.

Depending the results of the main interim analysis, the main DB could be slightly modified and several sub analyses could be proposed after sensitivity analyses.

The objectives and event variables would vary with the precise analysis performed.

RESEARCHERS AND AUTHORSHIP.

Following HOPE rules, to avoid potential duplicates, an unique online account is accepted per hospital. Within each center, the researchers will decide themselves the main researcher (maximum 2 principal investigators,) and the collaborators (maximum 15).

HOPE2_v2_Last review 14.02.2021



They are accepted as collaborators, physicians, nurses, students, and other personnel under the supervision of local MD/DO/PhD investigators.

The order of authorship will be established based on the recruitment (valid cases) in HOPE 2. All study researchers and collaborators will be included in the HOPE 2 group.

HOPE or HOPE 2 are not audited records, so each researcher is responsible and vouch for the veracity and accuracy of their included data.

The database will be made available to participating researchers who wish to carry out sub-analyses of their interest, upon reasonable request.

PRELIMINARY AGENDA AND ROADMAP.

10th February 2021: Research Ethics committee approval.

February-15th March: DB design and preparation.

15-25th March 2021: National and international invitations to participate submission.

15-31st March 2021: Activation of HOPE 2 study invitation links. Once participation in the study is approved, your center will be registered and the researcher will be able to set a login and password. Then, you could enter the data on the web. For center previously participating in HOPE, the researcher's account will be reactivated.

May 2021: DB exportation. Query resolution phase. Interim analysis.

16-30th June: Analysis and development of statistical models, (propensity scores, etc.).

30th June- 15th July 2021: preliminary results.

31st september 2021: Final HOPE 2 enrollment period.

1-15th October: DB exportation. Query resolution phase. DB closure.

15th October-15th november 2021: Analysis and development of statistical models. Manuscripts.

January 2022: Final HOPE 2 results.

The final date of registration/follow up is sept 31st, 2021

SCIENTIFIC COORDINATION: Iván J. Núñez-Gil, MD, PhD. Carlos Macaya, MD, PhD.

SCIENTIFIC COMMITTEE AND LIST OF PARTICIPATING HOSPITALS: Available updated at www.HopeProjectMD.com.

HOPE2_v2_Last review 14.02.2021



COORDINATOR CENTRE: HOSPITAL CLINICO SAN CARLOS, MADRID, SPAIN.

PROMOTER: Fundación interhospitalaria para la Investigación cardiovascular, **FIC**. Paseo del Pintor Rosales, N18, izq. 28008, Madrid. Spain. CIF: G-81563801.

PI'S REFERENCES ON COVID-19, UPDATED TO MARCH 2021.

1: Cormican DS, Winter D, McHugh S, Sonny A, Crowley J, Yu R, Barrack F, Núñez-Gil JJ, Ramakrishna H. Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. *J Cardiothorac Vasc Anesth*. 2021 Mar;35(3):932-943. doi: 10.1053/j.jvca.2020.05.035. Epub 2020 Jun 3. PMID: 32601001; PMCID: PMC7836849.

2: Uribarri A, Núñez-Gil JJ, Aparisi A, Becerra-Muñoz VM, Feltes G, Trabattoni D, Fernández-Rozas I, Viana-Llamas MC, Pepe M, Cerrato E, Capel-Astrua T, Romero R, Castro-Mejía AF, El-Battrawy I, López-País J, D'Ascenzo F, Fabregat-Andres O, Bardají A, Raposeiras-Roubin S, Marín F, Fernández-Ortiz A, Macaya C, Estrada V; HOPE COVID-19 Investigators. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. *J Nephrol*. 2020 Aug;33(4):737-745. doi: 10.1007/s40620-020-00790-5. Epub 2020 Jun 29. PMID: 32602006; PMCID: PMC7322375.

3: Núñez-Gil JJ, Estrada V, Fernández-Pérez C, Fernández-Rozas I, Martín-Sánchez FJ, Macaya C. The COVID-19 curve, health system overload, and mortality. *Emergencias*. 2020 Ago;32(4):293-295. English, Spanish. PMID: 32692012.

4: Bianco M, Biolè CA, Campagnuolo S, Pietrangiulillo F, Spirito A, Galluzzo A, Nuñez-Gil I, Destefanis P, Luciano A, Carvalho P, Varalda GP, Previti A, Gravellone M, Travieso Gonzalez A, Ugo F, Pivano G, Rametta F, Perboni A, Pozzi

HOPE2_v2_Last review 14.02.2021



R, Montagna L, Cerrato E. COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients. *Int J Cardiol Heart Vasc.* 2020 Oct;30:100637. doi: 10.1016/j.ijcha.2020.100637. Epub 2020 Sep 11. PMID: 32953967; PMCID: PMC7486053.

5: Núñez-Gil IJ, Estrada V, Fernández-Pérez C, Feltes G, Vedia O, Vergara-Uzategui CE, Moreno-Menguía VH, Cerrato E, D'Ascenzo F, Raposeiras-Roubin S, Martín-Sánchez FJ, Alfonso-Rodríguez E, Huang J, Ramakrishna H, Gil-Higes E, Fernández-Ortiz A, Macaya C. Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design. *Contemp Clin Trials Commun.* 2020 Dec;20:100654. doi: 10.1016/j.conctc.2020.100654. Epub 2020 Sep 23. PMID: 32989425; PMCID: PMC7510540.

6: Rivera-Caravaca JM, Núñez-Gil IJ, Vivas D, Viana-Llamas MC, Uribarri A, Becerra-Muñoz VM, Trabattoni D, Fernández Rozas I, Feltes G, López-Pais J, El-Battrawy I, Macaya C, Fernandez-Ortiz A, Estrada V, Marín F; HOPE COVID-19 Investigators. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. *Eur J Clin Invest.* 2021 Jan;51(1):e13436. doi: 10.1111/eci.13436. Epub 2020 Nov 7. PMID: 33080051; PMCID: PMC7645931.

7: Núñez-Gil IJ, Fernández-Pérez C, Estrada V, Becerra-Muñoz VM, El-Battrawy I, Uribarri A, Fernández-Rozas I, Feltes G, Viana-Llamas MC, Trabattoni D, López-Pais J, Pepe M, Romero R, Castro-Mejía AF, Cerrato E, Astrua TC, D'Ascenzo F, Fabregat-Andres O, Moreu J, Guerra F, Signes-Costa J, Marín F, Buosenso D, Bardají A, Raposeiras-Roubin S, Elola J, Molino Á, Gómez-Doblas JJ, Abumayyaleh M, Aparisi Á, Molina M, Guerri A, Arroyo-Espliguero R, Assanelli E, Mapelli M, García-Acuña JM, Brindicci G, Manzone E, Ortega-Armas ME, Bianco M, Trung CP, Núñez MJ, Castellanos-Lluch C, García-Vázquez E, Cabello-Clotet N, Jamhour-Chelh K, Tellez MJ, Fernández-Ortiz A, Macaya C; HOPE COVID-19 Investigators. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. *Intern Emerg Med.* 2020 Nov 9:1–10. doi: 10.1007/s11739-020-02543-5.

HOPE2_v2_Last review 14.02.2021



Epub ahead of print. PMID: 33165755; PMCID: PMC7649104.

8: Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, García Aguado M, Romero R, Huang J, Mulet A, Ugo F, Rametta F, Liebetrau C, Aparisi A, Fernández-Rozas I, Viana-Llamas MC, Feltes G, Pepe M, Moreno-Rondón LA, Cerrato E, Raposeiras-Roubín S, Alfonso E, Carrero-Fernández A, Buzón-Martín L, Abumayyaleh M, Gonzalez A, Fernández Ortiz A, Macaya C, Estrada V, Fernández-Pérez C, Gómez-Doblas JJ. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. *Age Ageing*. 2021 Feb 26;50(2):326-334. doi: 10.1093/ageing/afaa258. PMID: 33201181; PMCID: PMC7717146.

9: Ruiz-Sánchez JG, Núñez-Gil IJ, Cuesta M, Rubio MA, Maroun-Eid C, Arroyo-Espliguero R, Romero R, Becerra-Muñoz VM, Uribarri A, Feltes G, Trabattoni D, Molina M, García Aguado M, Pepe M, Cerrato E, Alfonso E, Castro Mejía AF, Roubin SR, Buzón L, Bondia E, Marin F, López Pais J, Abumayyaleh M, D'Ascenzo F, Rondano E, Huang J, Fernandez-Perez C, Macaya C, de Miguel Novoa P, Calle-Pascual AL, Estrada Perez V, Runkle I; HOPE COVID-19 investigators. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. *Front Endocrinol (Lausanne)*. 2020 Nov 30;11:599255. doi: 10.3389/fendo.2020.599255. PMID: 33329400; PMCID: PMC7734292.

10: Núñez-Gil IJJ, Fernández-Ortiz A, Maroud Eid C, Huang J, Romero R, Becerra-Muñoz VM, Uribarri A, Feltes G, Trabattoni D, Fernandez-Rozas I, Viana-Llamas MC, Pepe M, Cerrato E, Bertaina M, Capel Astrua T, Alfonso E, Castro-Mejía AF, Raposeiras-Roubin S, D'Ascenzo F, Espejo Paeres C, Signes-Costa J, Bardaji A, Fernandez-Pérez C, Marin F, Fabregat-Andres O, Akin I, Estrada V, Macaya C. Underlying heart diseases and acute COVID-19 outcomes. *Cardiol J*. 2020 Dec 21. doi: 10.5603/CJ.a2020.0183. Epub ahead of print. PMID: 33346365.

11: Signes-Costa J, Núñez-Gil IJ, Soriano JB, Arroyo-Espliguero R, Eid CM, Romero R, Uribarri A, Fernández-Rozas I, Aguado MG, Becerra-Muñoz VM, Huang J,

HOPE2_v2_Last review 14.02.2021



Pepe M, Cerrato E, Raposeiras S, Gonzalez A, Franco-Leon F, Wang L, Alfonso E,

Ugo F, García-Prieto JF, Feltes G, Abumayyaleh M, Espejo-Paeres C, Jativa J,

Masjuan AL, Macaya C, Carbonell Asíns JA, Estrada V; HOPE COVID-19

investigators. Prevalence and 30-Day Mortality in Hospitalized Patients With

Covid-19 and Prior Lung Diseases. Arch Bronconeumol. 2020 Dec

16:S0300-2896(20)30535-4. doi: 10.1016/j.arbres.2020.11.012. Epub ahead of

print. PMID: 33423874; PMCID: PMC7744014.

12: Pepe M, Maroun-Eid C, Romero R, Arroyo-Espliguero R, Fernández-Rozas I,

Aparisi A, Becerra-Muñoz VM, García Aguado M, Brindicci G, Huang J, Alfonso-

Rodríguez E, Castro-Mejía AF, Favretto S, Cerrato E, Albiol P, Raposeiras-Roubin

S, Vedia O, Feltes Guzmán G, Carrero-Fernández A, Perez Cimarra C, Buzón L,

Jativa Mendez JL, Abumayyaleh M, Corbi-Pascual M, Macaya C, Estrada V, Nestola

PL, Biondi-Zoccai G, Núñez-Gil IJ. Clinical presentation, therapeutic approach,

and outcome of young patients admitted for COVID-19, with respect to the elderly

counterpart. Clin Exp Med. 2021 Feb 8:1–20. doi: 10.1007/s10238-021-00684-1.

Epub ahead of print. PMID: 33555436; PMCID: PMC7868661.

13: Uribarri A, Núñez-Gil IJ, Aparisi Á, Arroyo-Espliguero R, Maroun Eid C,

Romero R, Becerra-Muñoz VM, Feltes G, Molina M, García-Aguado M, Cerrato E,

Capel-Astrua T, Alfonso-Rodríguez E, Castro-Mejía AF, Raposeiras-Roubín S,

Espejo C, Pérez-Solé N, Bardají A, Marín F, Fabregat-Andrés Ó, D'ascenzo F,

Santoro F, Akin I, Estrada V, Fernández-Ortiz A, Macaya C; HOPE COVID-19

investigators. Atrial fibrillation in patients with COVID-19. Usefulness of the

CHA₂DS₂-VASc score: an analysis of the international HOPE

COVID-19 registry. Rev Esp Cardiol (Engl Ed). 2021 Jan 13:S1885-5857(21)00001-3.

doi: 10.1016/j.rec.2020.12.009. Epub ahead of print. PMID: 33583755; PMCID:

PMC7836821.

14: Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregón JA, Uribe-Heredia G,

Núñez-Gil I, García-Magallón B, Torán-Martínez CG, Castillo-Sandoval A, Díaz-

Caraballo E, Rodríguez-Guinea I, Domínguez-López J. Hypoalbuminemia on admission

HOPE2_v2_Last review 14.02.2021



in COVID-19 infection: An early predictor of mortality and adverse events. A

retrospective observational study. *Med Clin (Barc)*. 2021 Jan

28:S0025-7753(21)00032-4. doi: 10.1016/j.medcli.2020.12.018. Epub ahead of

print. PMID: 33627230; PMCID: PMC7843155.

15: Porta-Etessam J, Núñez-Gil IJ, González García N, Fernandez-Perez C, Viana-Llamas MC, Eid CM, Romero R, Molina M, Uribarri A, Becerra-Muñoz VM, Aguado MG, Huang J, Rondano E, Cerrato E, Alfonso E, Mejía AFC, Marin F, Roubin SR, Pepe M, Feltes G, Maté P, Cortese B, Buzón L, Mendez JJ, Estrada V. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. *Infection*. 2021 Mar 1:1–8. doi: 10.1007/s15010-021-01587-9. Epub ahead of print. PMID: 33646505; PMCID: PMC7917537.

16: Salgado-Aranda R, Pérez-Castellano N, Núñez-Gil I, Orozco AJ, Torres-Esquivel N, Flores-Soler J, Chamaisse-Akari A, McInerney A, Vergara-Uzategui C, Wang L, González-Ferrer JJ, Filgueiras-Rama D, Cañadas-Godoy V, Macaya-Miguel C, Pérez-Villacastín J. Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study. *Infect Dis Ther*. 2021 Mar 14:1–14. doi: 10.1007/s40121-021-00418-6. Epub ahead of print. PMID: 33715099; PMCID: PMC7955903.

17: Ayerbe L, Risco-Risco C, Núñez-Gil I, Perez-Piñar M, Ayis S. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? *Lancet Rheumatol*. 2021 Mar;3(3):e172. doi: 10.1016/S2665-9913(21)00031-X. Epub 2021 Jan 27. PMID: 33655225; PMCID: PMC7906731.

18: Bertaina M, Nuñez-Gil IJ, Franchin L, Fernández Rozas I, Arroyo-Espliguero R, Viana-Llamas MC, Romero R, Maroun Eid C, Uribarri A, Becerra-Muñoz VM, Huang J, Alfonso E, Marmol-Mosquera F, Ugo F, Cerrato E, Fernandez-Presa L, Raposeiras Roubin S, Feltes Guzman G, Gonzalez A, Abumayyaleh M, Fernandez-Ortiz A, Macaya

HOPE2_v2_Last review 14.02.2021



C, Estrada V; HOPE COVID-19 investigators. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry. *Emerg Med J.* 2021 Mar 16;emermed-2020-210411. doi: 10.1136/emermed-2020-210411. Epub ahead of print. PMID: 33727235.

19: Uribarri A, Núñez-Gil IJ, Aparisi Á, Arroyo-Espiguero R, Eid CM, Romero R, Becerra-Muñoz VM, Feltes G, Molina M, García-Aguado M, Cerrato E, Capel-Astrua T, Alfonso-Rodríguez E, Castro-Mejía AF, Raposeiras-Roubín S, Espejo C, Pérez-Solé N, Bardají A, Marín F, Fabregat-Andrés Ó, D'ascenzo F, Santoro F, Akin I, Estrada V, Fernández-Ortiz A, Macaya C; en representación de los investigadores del HOPE COVID-19. Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19 [Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry]. *Rev Esp Cardiol.* 2021 Mar 2. Spanish. doi: 10.1016/j.recresp.2020.12.014. Epub ahead of print. PMID: 33678938; PMCID: PMC7923850.

20: Salinas P, Travieso A, Vergara-Uzategui C, Tirado-Conte G, Macaya F, Mejía-Rentería H, Nombela-Franco L, Núñez-Gil IJ, Gonzalo N, Jiménez-Quevedo P, Pérez-Vizcayno MJ, Escaned J, Fernández-Ortiz A. Clinical Profile and 30-Day Mortality of Invasively Managed Patients with Suspected Acute Coronary Syndrome During the COVID-19 Outbreak. *Int Heart J.* 2021 Mar 17. doi: 10.1536/ihj.20-574. Epub ahead of print. PMID: 33731529.

HOPE2_v2_Last review 14.02.2021